Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 5/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 3/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 7/20 | 0.36 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.36 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6206273 | 0.81 | PNMT (0.47) | PNMTACHE | |
| SCHEMBL6974545 | 0.76 | ACHE (0.66) | ACHE | |
| SCHEMBL17675410 | 0.74 | METAP1 (0.44) | ACHE | |
| SCHEMBL6971063 | 0.73 | ACHE (0.64) | ACHE | |
| SCHEMBL7847032 | 0.73 | METAP1 (0.43) | ACHE | |
| SCHEMBL1180262 | 0.72 | ACHE (0.69) | ACHE | |
| SCHEMBL6205822 | 0.72 | L3MBTL1 (0.33) | ACHEPTGS2PTGS1 | |
| SCHEMBL1808330 | 0.71 | PTPRC (0.47) | PNMTACHE | |
| SCHEMBL8317204 | 0.71 | HTR2C (0.46) | — | |
| SCHEMBL1003926 | 0.69 | PBRM1 (0.52) | PNMTKDM1APTGS2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1098891-B1 | POLYCYCLIC THIAZOLIDIN-2-YLIDENE AMINES, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | AVENTIS PHARMA GMBH (DE) | 2005-08-10 | — | — | EP | disclosed |
| EP-1157015-B1 | USE OF POLYCYCLIC 2-AMINO-THIAZOLE SYSTEMS FOR THE MANUFACTURE OF MEDICAMENTS FOR THE TREATMENT OF LIPOMETABOLIC DISORDERS, OBESITAS AND TYP II DIABETES | AVENTIS PHARMA GMBH (DE) | 2005-05-11 | — | — | EP | disclosed |
| EP-1173176-B1 | UTILIZATION OF POLYCYCLIC 2-AMINO-THIAZOLE SYSTEMS IN THE PRODUCTION OF MEDICAMENTS FOR PROPHYLAXIS OR TREATMENT OF OBESITY | AVENTIS PHARMA GMBH (DE) | 2004-05-26 | — | — | EP | disclosed |
| US-6476059-B1 | Use of polycyclic 2-aminothiazole systems for the treatment of obesity | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-11-05 | — | — | US | disclosed |
| EP-1157015-A1 | POLYCYCLIC 2-AMINO-THIAZOLE SYSTEMS, METHOD FOR THE PRODUCTION THEREOF AND MEDICAMENT CONTAINING SAID COMPOUNDS | Aventis Pharma Deutschland GmbH (DE) | 2001-11-28 | — | — | EP | disclosed |
| EP-1157013-A1 | POLYCYCLIC THIAZOLE-2-YLIDES AMINES, METHOD FOR THE PRODUCTION THEREOF AND THEIR UTILIZATION AS MEDICAMENTS | Aventis Pharma Deutschland GmbH (DE) | 2001-11-28 | — | — | EP | disclosed |
| US-6288093-B1 | COMPOUNDS SUCH AS (6-CHLORO-3-METHYL-3,8-DIHYDROINDENO (1,2-D)THIAZOL-2-YLIDENE)METHYLAMINE HYDROBROMIDE USED AS ANORECTICS AND ANTIDIABETICS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-09-11 | — | — | US | disclosed |
| US-6288094-B2 | COMPOUNDS SUCH AS (6-CHLORO-3-METHYL-3,8-DIHYDROINDENO (1,2-D)THIAZOL-2-YLIDENE)METHYLAMINE HYDROBROMIDE USED AS ANORECTICS AND ANTIDIABETICS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-09-11 | — | — | US | disclosed |
| US-20010011096-A1 | Polycyclic thiazol-2-ylidene amines, processes for their preparation and their use as medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2001-08-02 | — | — | US | disclosed |
| US-6251922-B1 | TREATMENT OF OBESITY AND DIABETES | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-06-26 | — | — | US | disclosed |
| EP-1098891-A1 | POLYCYCLIC THIAZOLIDIN-2-YLIDENE AMINES, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | Aventis Pharma Deutschland GmbH (DE) | 2001-05-16 | — | — | EP | disclosed |
| US-6207689-B1 | AS ANORECTICS AND IN THE TREATMENT OR PROPHYLAXIS OF TYPE II DIABETES | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2001-03-27 | — | — | US | disclosed |
| US-6159996-A | Polycyclic thiazolidin-2-ylidene amines, process for their preparation, and their use as pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-12-12 | — | — | US | disclosed |
| WO-2000051996-A1 | POLYCYCLIC THIAZOLE-2-YLIDES AMINES, METHOD FOR THE PRODUCTION THEREOF AND THEIR UTILIZATION AS MEDICAMENTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-09-08 | — | — | WO | disclosed |
| WO-2000051995-A1 | POLYCYCLIC 2-AMINO-THIAZOLE SYSTEMS, METHOD FOR THE PRODUCTION THEREOF AND MEDICAMENT CONTAINING SAID COMPOUNDS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-09-08 | — | — | WO | disclosed |
| WO-2000004006-A1 | POLYCYCLIC THIAZOLIDIN-2-YLIDENE AMINES, METHOD FOR THE PRODUCTION AND USE THEREOF AS MEDICAMENTS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2000-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010011096-A1 | Polycyclic thiazol-2-ylidene amines, processes for their preparation and their use as medicaments | SLC5A2, OTC, GOT2 | PNMT 21/4885KDM1A 1957/4885ACHE 2506/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.